Boothbay Fund Management’s Relmada Therapeutics RLMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.4M Sell
372,300
-192,459
-34% -$944K 0.02% 776
2026
Q2
$3.91M Sell
564,759
-164,296
-23% -$1.15M 0.05% 427
2026
Q1
$5.07M Sell
729,055
-106,245
-13% -$503K 0.07% 315
2025
Q4
$4.03M Buy
835,300
+142,064
+20% +$476K 0.06% 354
2025
Q3
$1.39M Buy
+693,236
New +$665K 0.02% 698
2023
Q3
– Sell
-12,792
Closed -$31.5K – 2020
2023
Q2
$31.5K Hold
12,792
– – ﹤0.01% 1698
2023
Q1
$28.9K Hold
12,792
– – ﹤0.01% 2047
2022
Q4
$44.6K Buy
+12,792
New +$112K ﹤0.01% 1882
2021
Q3
– Sell
-34,353
Closed -$1.1M – 2143
2021
Q2
$1.1M Buy
34,353
+1,142
+3% +$39.7K 0.04% 644
2021
Q1
$1.17M Buy
+33,211
New +$1.16M 0.04% 519

Other funds holding RLMD

Boothbay Fund Management's RLMD Position: Q3 2026 in Review

Boothbay Fund Management reduced its Relmada Therapeutics (RLMD) stake by 34% in Q3 2026, selling an estimated $944K and leaving 372,300 shares worth $1.4M. The position accounts for 0.02% of the portfolio, ranked #776.

Boothbay Fund Management first reported a position in RLMD in Q1 2021 and has held it in 10 quarters since. The position peaked at $5.07M in Q1 2026. 135 funds tracked by Wall St. Rank hold RLMD as of Q3 2026.

  • Boothbay Fund Management held 372,300 shares of Relmada Therapeutics worth $1.4M as of Q3 2026.
  • Boothbay Fund Management sold 192,459 Relmada Therapeutics shares in Q3 2026, an estimated $944K.
  • Relmada Therapeutics made up 0.02% of Boothbay Fund Management's portfolio in Q3 2026, its #776 holding.
  • Boothbay Fund Management first reported a position in Relmada Therapeutics in Q1 2021 and has held it in 10 quarters since.
  • Boothbay Fund Management's Relmada Therapeutics position peaked at $5.07M in Q1 2026.
  • 135 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2026.

Based on Boothbay Fund Management's 13F filing for Q3 2026, filed 16 Nov 2026.